GB2056449A - 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides - Google Patents

8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides Download PDF

Info

Publication number
GB2056449A
GB2056449A GB8025795A GB8025795A GB2056449A GB 2056449 A GB2056449 A GB 2056449A GB 8025795 A GB8025795 A GB 8025795A GB 8025795 A GB8025795 A GB 8025795A GB 2056449 A GB2056449 A GB 2056449A
Authority
GB
United Kingdom
Prior art keywords
triazolo
phenyl
compound
parts
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB8025795A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of GB2056449A publication Critical patent/GB2056449A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds corresponding to the following general formula: <IMAGE> wherein R represents hydrogen, C1-C4 alkyl, C2-C4 alkoxyalkyl, C2-C4 alkenyl or C2-C4 alkynyl; and R1 represents hydrogen or C1 or C2 1- oxoalkyl, are pharmaceutically active and may be used as diuretic agents, e.g. in pharmaceutical compositions.

Description

SPECIFICATION 8-substituted 7-phenyl-1 2,4-triazolo [4,3-c] pyrimidines-5-amines and amides, preparation and pharmaceutical use thereof This invention relates to 8-substituted 7phenyl-1 ,2,4-triazolo[4,3-c]pyrimidines-5-amines and amides, preparation and pharmaceutical use thereof.
The present invention provides a compound corresponding to the following general formula:
wherein R represents hydrogen, alkyl containing from 1 to 4 carbon atoms, or alkoxyalkyl, alkenyl or alkynyl containing from 2 to 4 carbon atoms; and R1 represents hydrogen or 1-oxoalkyl containing 1 or 2 carbon atoms.
Those alkyl radicals containing from 1 to 4 carbon atoms and represented by R are typified by methyl, ethyl, propyl and butyl and the corresponding branched-chain isomers.
Those alkoxyalkyl radicals containing from 2 to 4 carbon atoms and represented by R are typified by methoxymethyl, methoxyethyl, 2methoxypropyl, 3-methoxypropyl, ethoxymethyl, 1-ethoxyethyl, 2-ethoxyethyl, ethoxymethyl, propoxymethyl and (1 -methylethoxyethyl).
Those alkenyl and alkynyl radicals containing from 2 to 4 carbon atoms and represented by R are typified by ethenyl, 1-propenyl, 2-propenyl, 1butenyl 2-butenyl, 3-butenyl, ethynyl, 1propynyl, 2-propynyl, 1-butynyl, 2-butynyl and 3butynyl and the corresponding branched chain isomers.
The 1 -oxoalkyl radicals containing 1 or 2 carbon atoms and represented by RX are carbonyl and acetyl.
Such compounds corresponding to the following general formula:
wherein R is defined above; are preferred. It is particularly preferred that R should represent alkyl containing from 1 to 4 carbon atoms or alkoxyalkyl containing from 1 to 4 carbon atoms.
The present compounds are useful because of the valuable pharmacological properties thereof.
For example, they are potent diuretics. When assayed for the capacity to increase urine volume as described by Lipschitz et al. [J. Pharmacol. Exp.
Therap., 7997(1943)] and assigned potencies based upon parallel dose response curves in accordance with Finney (Statistical Method in Biological Assay, 2nd ed., Charles Griffin 8 Company, Limited, London, 1964]. 8-methyl-7phenyl- 1 ,2,4-triazolo[4,3-c] pyri midine-5-amine and 8-(2-ethoxyethyl )-7-phenyl-[ 1 ,2 ,4]triazolo [4,3-c] pyrimidine-5-amine were found to be 1.2 and 2.7 times as potent as hydrochlorothiazide, respectively. The latter compound is particularly preferred. The typical dosage of hydrochlorothiazide as a diuretic for use in humans is 25 or 50 mg per oral administration.
ror therapeutic purposes, the present compounds are generally combined with one or more pharmaceutically acceptable carriers.
diluents or adjuvants appropriate to the indicated route of administration. If per os, they may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, gelatin, acacia, sodium alginate, polyvinylpyrolidone, and/or polyvinyl alcohol, and thus tableted or encapsulated for convenient administration; alternatively, they maybe dissolved in water or a comparably innocuous liquid. Parenteral administration may be effected via sterile fluid admixture with water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.Other adjuvants and modes of administration are well and widely known in the pharmaceutical art; see, for example F. W. Martin et al., "Remington's Pharmaceutical Sciences", 14th ed., Merck Publishing Co., Eaton, Pa., 1965.
Appropriate dosages, in given instances of course depend upon the nature and severity of the condition treated, the route of administration and the species of mammal involved, including its size and individual idiosyncrasies which obtain.
The present invention also provides such compositions and such pharmaceutical use.
The amines according to the present invention may be prepared by reacting 4-chloro-6phenylpyrimidin-2-amines corresponding to the following general formula:
wherein R is defined as above; with formylhydrazine in dimethylforma mide. The resulting amines may be crystallized in water and recrystallized from methanol.
The amides according to the present invention may be prepared by reacting the corresponding amines with formic or acetic anhydride, depending upon the desired amide.
Alternatively, the present amides may be prepared by reacting appropriate N-(4-chloro-6phenylpipimidin-2-yl)amides corresponding to the following general formula:
wherein R is defined as above; and R1' represents formyl or acetyl; forformylhydrazine in dimethylformamide. The solid product is obtained by the addition of water.
The present invention also provides such a process for the preparation of the above compounds.
The following Examples illustrate the present invention. Unless otherwise indicated, temperatures are given in degrees centigrade and amounts in parts, by weight.
EXAMPLE 1 5.5 parts of 4-chloro-5-methyl-6phenylpyrimidin-2-amine and 3.0 parts of formylhydrazine are added to 50 parts, by volume of dimethylformamide containing 5.0 parts of molecular sieve 3A and refluxed under nitrogen for 2 hours. After standing for 16 hours at room temperature, the solution is poured into cold water. The yellow crystalline product is filtered off, washed with water and dried. The product is recrystallised from methanol to give, as bright yellow needles melting at 258-2600C, 8methyl-7-phenyl-1 ,2,4-triazolo[4,3-c]pyrimidin-5- amine:
EXAMPLE 2 10.0 parts of 4-chloro-5-(2-ethoxyethyl)-6phenylpyrimidin-2-amine and 3.0 parts of formylhydrazine are added to 80 parts, by volume, of dimethylformamide containing 8.0 parts of molecular sieve 3A and refluxed under nitrogen for 2 hours.After standing for 1 6 hours at room temperature, the solution is poured into cold water. The crystalline product is filtered off, washed with water and dried. The product is recrystallized from methanol to give 8-(2ethoxyethyl)-7-phenyl-] 1 ,2,4jtriazolo[4,3- c]pyrimidin-5-amine melting at 1540 C:
EXAMPLE 3 1.7 parts of 4-chloro-6-phenyl-5-(2-propynyl) pyrimidin-2-amine and 0.84 part of formylhydrazine are added to 20 parts, by volume, of dimethylformamide containing 2.0 parts of molecular sieve 3A and refluxed under nitrogen for 2 hours. The solution is allowed to cool and is poured into cold water. The crystalline product is filtered off, washed with water and dried.The product is recystallized from methanol to give 7phenyl-8-(2-propynyl) [1 ,2,4]triazolo[4,3- c]pyrimidin-5-amine melting at 2400 C:
EXAMPLE 4 6.6 parts of 8-methyl-7-phenyl-1 ,2,4- triazolo[4,3-cjpyrimidin-5-amine (Example 1) is suspended in 50 parts, by volume, of pyridine and 10 parts, by volume, of acetic anhydride. The solution is stirred at room temperature for about 18 hours until a clear solution is formed. After about 21 hours, turbidity develops and a solid gradually forms. After standing for about 40 hours, most of the solvent is removed in vacua. The residue is stirred in water, filtered, washed with water and dried. The product is recrystallized from methanol to give N-(8-methyl-7-phenyl [1 ,2,4]triazolo[4,3-c]pyrimidin-5-yl]aceta mide melting at 2100C:
EXAMPLE 5 Alternatively, the product of Example 4, N-(8 methyl-7-phenyl-[ 1 ,2,4]triazolo[4,3-cjpyrimidine- 5-yl] acetamide, may-be obtained using the appropriate chlorinated pyrimidine. 7.85 parts of N-(4-chloro-5-methyl-6-phenylpyrimidine-2- yl)acetamide:
is added to 6.0 parts of formylhydrazine and 60 parts, by volume, of dimethylformamide. The solution is heated to reflux under nitrogen for 2.5 hours. The solution is allowed to cool and stand at room temperature for 1 6 hours. The clear solution is poured into cold water with stirring. A bright yellow crystalline material is obtained.The material is filtered, washed with water, dried and recrystallized from methanol to give the desired product.
EXAMPLE 6 6.4 parts of N-[4-chloro-5-(2-ethoxyethyl)-6phenylpyrimidin-2-yl]acetamide and 2.4 parts of formylhydrazine are added to 60 parts, by volume, of dimethylformamide containing 6.0 parts of molecular sieve 3A and refluxed under nitrogen for 1 hour. The golden orange solution is then allowed to cool and is poured into water. A bright yellow material is obtained, which is then filtered off, washed with water and dried to give N-[8-(2 ethoxyethyl)-7-phenyl-[ ,2,4]triazolo[4,3- c]pyrimidin-2-yl) acetamide melting at 75-760C:
Having illustrated the preparation of the present compounds, the pharmaceutical use thereof will now be illustrated.
Pharmaceutical formulations were prepared in the following manner, amounts indicating the relative amounts per tablet, capsule, suppository or parenteral product.
Tablets 25 mg of a representative compound, e.g. 8-(2- ethoxyethyl)-7-phenyl-[1,2,4]triazolo[4,3- c]pyrimidine-5-amine were dissolved in isopropyl alcohol and distributed on 191.2 mg. of lactose.
The mixture was air-dried and passed through a 40 mesh screen. 25 mg of corn starch and 7.5 mg of polyvinylpyrrolidone were added to the drug substance lactose mixture, mixed thoroughly and passed through a 40 mesh screen. The mixture was then granulated using isopropyl alcohol, spread on trays and dried at about 490C (1200F.) for 1 6 hours. The dried granulation was then screened. The granules were mixed thoroughly with 1.3 mg of magnesium stearate and the mixture compressed into tablets of the appropriate size. There was thus obtained a tablet having a concentration of active ingredient of 25 mg/tablet.
CAPSULES 25 mg of 8-(2-ethoxyethyl)-7-phenyl [1 ,2,4]triazolo[4,3-c]pyrimidine-5-amine were mixed thoroughly with 1 77.5 mg of corn starch and 177.5 mg of lactose, screened through a 40 mesh screen and remixed. 20 mg of talc were added and the mixture was thoroughly mixed and filled into the appropriate hard gelatin capsule by hand or machine using 400 mg fill per capsule.
There was thus obtained a capsule having a concentration of active ingredients of 25 mg capsule.
In the preparation of tablets and capsules using the present compounds, a variety of excipients may be used. For example: Sugars, such as lactose, sucrose, mannitol, or sorbitol; starches, such as corn starch, tapioca starch, or potato starch; cellulose derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, or methyl cellulose; gelatine; calcium phosphates, such as dicalcium phosphate or tricalcium phosphate; sodium sulphate; calcium sulphate; polyvinylpyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates, such as magnesium stearate; stearic acid vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil; surfactants (non-ionic, cationic, anionic); ethylene glycol polymers; betacyclodextrin; fatty alcohols; hydrolyzed cereal solids; as well as other non-toxic compatible fillers, binders, disintegrants, and lubricants commonly used in pharmaceutical formulations.
PARENTERAL PRODUCTS 10 mg of 8-(2-ethoxyethyl)-7-phenyl [1 ,2,4jtriazolo[4,3-c]pyrim din-S-amine was dissolived in 2 ml. of ethanol and 5 ml of sesame oil, filtered and filled into an ampoule and sealed.
the ampoule was then sterilized by an appropriate procedure. There was thus obtained an ampoule having a concentration of active ingredient 10 mg/5ml.
In the preparation of parenteral products using the present compounds a variety of vehicles and solublizers may be used. For example: Vegetable oils, such as peanut, corn, cottonseed, sesame oil, benzyl alcohol, saline, phosphate buffer, water, ethylene glycol polymers, urea, dimethylacetamide, "Triton" (Registered Trade Mark), dioxolanes, ethyl carbonate ethyl lactate, glycerol formal, isopropyl myristate, surfactants (non-ionic, cationic, anionic), polyalcohols and ethanol.
SUPPOSITORIES 975 mg of cocoa butter were melted, preferably using a water or steam bath to avoid local overheating, then 25 mg of 8-(2 ethoxyethyl)-7-phenyl-[1,2,4]triazolo[4,3- c]pyrimidin-5-amine was either emulsified or suspended in the melt.
The mass was then poured into cooled chromeplated metal moulds and the suppository was readily solidified. The total weight of the suppository was 1000 mg.
In the preparation of suppositories using the present compounds a variety of vehicles and bases for suppository application may be used. For example; Triglycerides of oleic, palmitric, and stearic acids (cocoa butter), partially hydrogenated cottonseed oil, branched saturated fatty alcohols, such as Suppository base G, Hydrogenated coconut oil triglycerides of Ct2C, fatty acids, water dispersible vehicles, such as the polyethylene glycols, glycerin, gelatin, polyoxyl 40 sterarates, and polyethylene-4-sorbitan monostearates, and materials which may raise the melting point of the suppository base, such as beeswax and spermaceti.

Claims (13)

1.A compound corresponding to the following general formula:
wherein R represents hydrogen, C 1-c4alkyl C2-C4 alkoxyalkyl, C2-C4 alkenyl or C2-c4 alkynyl; and R1 represents hydrogen or C1-c2 1 - oxoalkyl.
2. A compound as claimed in claim 1 corresponding to the following general formula:
wherein R' represents C1 or C2 alkylene; R" represents C, or C2 alkyl; and P1 represents hydrogen or C, or C2 1 -oxoalkyl.
3. A compound as claimed in claim 2 corresponding to the following general formula:
wherein R' represents C, or C2 alkylene; and Rn represents CX or C2 alkyl.
4. A compound as claimed in claim 1 corresponding to the following general formula:
wherein R"' represents hydrogen, methyl, ethyl, ethyenyl or ethynyl.
5. N-(8-methyl-7-phenyl-[1 ,2,4]triazolo[4,3- cjpyrimidin-5-yljacetamide.
6. N-(8-(2-ethoxyethyl)-7-phenyl [1,2,4]triazolo[4,3-c] pyrimidin-5-amine.
7.8-rriethyl-7-phenyl-1,2,4-triazolo[4,3- c]pyrimidin-5-amine.
8. A process for the preparation of a compound as claimed in claim 1 substantially as herein described.
9. A process for the preparation of a compound as claimed in claim 1 substantially as herein described with reference to any one of the Examples.
10. A compound as claimed in claim 1 when prepared by a process as claimed in claim 8 or claim 9.
11. A pharmaceutical composition which comprises a compound as claimed in any of claims 1 to 7 or 10 and a pharmaceutically-acceptable carrier or diluent.
12. A composition as claimed in claim 11 substantially as herein described.
13. The use of a compound as claimed in any of claims 1 to 7 or 10 as a pharmaceutical.
GB8025795A 1979-08-08 1980-08-07 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides Withdrawn GB2056449A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470779A 1979-08-08 1979-08-08

Publications (1)

Publication Number Publication Date
GB2056449A true GB2056449A (en) 1981-03-18

Family

ID=22057763

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8025795A Withdrawn GB2056449A (en) 1979-08-08 1980-08-07 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides

Country Status (7)

Country Link
JP (1) JPS5632479A (en)
AU (1) AU531507B2 (en)
CA (2) CA1246064A (en)
CH (1) CH645898A5 (en)
DE (1) DE3029871C2 (en)
FR (1) FR2463143A1 (en)
GB (1) GB2056449A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056449A (en) 1979-08-08 1981-03-18 Searle & Co 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides
DK135184A (en) * 1983-03-03 1984-10-10 Riker Laboratories Inc TRIAZOL (4.3-C) - AND TRIAZOL (1.5-C) PYRIMIDINES
US4528288A (en) * 1983-05-02 1985-07-09 Riker Laboratories, Inc. Substituted triazolo[1,5-c]pyrimidines
US4532242A (en) * 1983-05-02 1985-07-30 Riker Laboratories, Inc. Substituted triazolo[4,3-c]pyrimidines
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
US4866063A (en) * 1988-12-22 1989-09-12 G. D. Searle & Co. Diol metabolites of 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
KR20210146296A (en) * 2019-04-03 2021-12-03 테라 스톤 가부시키가이샤 Triazolopyrimidines based on thymine nucleic acid base and method for producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1205144A (en) * 1957-06-14 1960-01-29 Farmaceutici Italia Process for the synthesis of 7-methyl-s. triazol (4, 3-c) pyrimidines substituted in position 5
US3284542A (en) 1963-03-22 1966-11-08 Rexall Drug Chemical Preparation of high impact compositions from vinyl aromatic monomers and rubbery diolefin polymers
US3244715A (en) 1964-10-30 1966-04-05 Smith Kline French Lab Phenylimidazo [4, 5-d] pyridazines
US3461123A (en) 1968-04-12 1969-08-12 Merck & Co Inc 1h-imidazo(4,5-b)pyrazin-2-ones and processes for their preparation
GB2056449A (en) 1979-08-08 1981-03-18 Searle & Co 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors

Also Published As

Publication number Publication date
CA1246063A (en) 1988-12-06
CA1246064B (en) 1988-12-06
AU531507B2 (en) 1983-08-25
DE3029871C2 (en) 1987-01-15
FR2463143A1 (en) 1981-02-20
CA1246064A (en) 1988-12-06
CA1246063B (en) 1988-12-06
CH645898A5 (en) 1984-10-31
JPH029592B2 (en) 1990-03-02
DE3029871A1 (en) 1981-02-26
FR2463143B1 (en) 1983-12-16
AU6115380A (en) 1981-02-12
JPS5632479A (en) 1981-04-01

Similar Documents

Publication Publication Date Title
KR100191774B1 (en) Pyrazolo(1,5-alpha)pyrimidine derivatives and anti-inflammatory agent containing them
US4886797A (en) Heterocyclic compounds and their preparation and use
US3930005A (en) Antiinflammatory agents and their use
KR900006753B1 (en) Process for preparation of 6-amino 7-hydroxy-4,5,6,7-tetrahydro imidazo (4,5,l-j,k)(1)-benzazepine-2(1h)-one and its salts
JPH08253457A (en) 2,8-disubstituted quinazolinone compound
US20060287296A1 (en) Preparation of hymenialdsine derivatives and use thereof
GB2056449A (en) 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides
FR2523582A1 (en) SUBSTITUTED 1H-PYRAZOLO (1,5-A) PYRIMIDINES, IN PARTICULAR USE AS ANTI-INFLAMMATORY AND ANALGESIC DRUGS, AND PROCESS FOR THEIR PREPARATION
US3573308A (en) 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
CA1038386A (en) Pyrrolo(3,4-d) pyrimidines and methods for their preparation
GB2142330A (en) Optionally 8-substituted 7-phenyl-1,2,4-triazolo [1.5-c] pyrimidines-5-amines and amides
EP0535104B1 (en) Heterocyclic compounds and their preparation and use
US4608375A (en) Quinazolinone derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
US5276028A (en) Imidazoquinoxaline compounds
AU638758B2 (en) Tetracyclic imidazoquinazoline derivatives, preparation and pharmaceutical compositions
US4405780A (en) 8-Substituted 7-phenyl-1,2,4,-triazolo[4,3-c]/[2,3-c]pyrimidines-5-amines and amides
SE436204B (en) 8-substituted 7-phenyl-1,2,4-triazalo(4,3-c)pyrimidine-5-amine or -amide compound
EP0152841B1 (en) 6-Substituted-5-phenyltetrazolo[1,5-a][1,2,4]triazolo[1,5-c]pyrimidines
US5260298A (en) Imidazatriazoloquinazoline compounds and their use
GB2048860A (en) N - (4 - azido - 5 - (2 - ethoxyethyl) - 6-phenyl - 2 - pyrimidinyl)acetamide and congeners
US3389136A (en) 10-(3-dimethylaminopropyl)-3-azapheno-thiazine and derivatives thereof
US3478023A (en) Pyrimido thiadiazines
WO1999061441A1 (en) Polymorphs of crystalline (7s,9as)-7-[ 3-cyanophenoxy] methyl-2-(5- fluoropyrimidin-2- yl)-2,3,4,6,7,8,9a -octahydro-1h-pyrido[1,2-a] pyrazine- monohydrochloride and their pharmaceutical compositions
JP2000344775A (en) New compound and medicinal composition containing the same

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)